Barclays analyst Steve Valiquette raised the firm’s price target on HCA Healthcare to $275 from $256 and keeps an Equal Weight rating on the shares. The company’s Q1 earnings beat has set the tone for better hospital sector growth in 2023 amid early inpatient admissions momentum, respectable surgical volume growth in inpatient and ASC setting, and subsiding labor pressure, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HCA:
- HCA Healthcare price target raised to $325 from $310 at Truist
- HCA Healthcare price target raised to $315 from $283 at RBC Capital
- HCA Healthcare price target raised to $350 from $325 at Jefferies
- HCA Healthcare price target raised to $310 from $280 at Deutsche Bank
- HCA Healthcare price target raised to $320 from $285 at Loop Capital
